New prognostic factors in breast cancer

Advances in Clinical and Experimental Medicine

Volumn 22, Issue 1, 2013, Pages 5-15

  Maciejczyk, Adam ^a  

^a Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

Author keywords

Breast cancer; Chemoresistance; KMplotter; Prognostic factors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BUB1 RELATED PROTEIN; MUCIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN S 100; Y BOX BINDING PROTEIN 1;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; GENE EXPRESSION; HUMAN; KAPLAN MEIER METHOD; MOLECULAR BIOLOGY; REVIEW;

EID: 84875822882     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Schnitt S: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathol 2010, 23, 60-64.
2. Niemiec J, Ryá J: Basal subtype of breast cancer: a morbid unit of a specific immunophenotypic characteristics [in Polish]. Pol J Pathol 2011, 4, 36-44.
3. Olszewski W, Chmielik E, Rys J: Pathomorphological selection of patients to systemic therapy [in Polish]. Pol J Pathol 2011, 4, 4, 28-33.
4. Rakha E, Reis-Filho J, Baehner F, Dabbs D, Decker T, Eusebi V, Fox S, Ichihara S, Jacquemier J, Lakhani S, Palacios J, Richardson A, Schnitt S, Schmitt F, Tan P-H, Tse G, Badve S, Ellis I: Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12, 207, 2-12.
5. Zmorzyński S, Karczmarek-Borowska B, Filip A: Molecular markers of carcinogenesis employed in diagnosis and planning of therapy in breast cancer. Współ Onkol 2008, 12, 5, 205-211.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406, 6797, 747-752.
7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield M, Hayes D, Bast Jr R: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25, 5287-5312. (Pubitemid 350232263)
8. Burstein H, Prestrud A, Seidenfeld J, Anderson H, Buchholz T Davidson N, Gelmon K, Giordano S, Hudis C, Malin J, Mamounas E, Rowden D, Solky A, Sowers M, Stearns V, Winer E, Somerfield M, Griggs J: American Society of Clinical Oncology Clinical Practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28, 3784-3796.
9. Debska S, Owecka A, Czernek U, Szydłowska-Pazera K, Habib M, Potemski P: Transmembrane transporters ABCC - structure, function and role in multidrug resistance of cancer cells. Postepy Hig Med Dosw 2011, 65, 552-561.
10. Bradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998, 16, 3674-3690. (Pubitemid 28506783)
11. Lenart K, Szyda A, Kielbasinski M, Dus D, Podolak-Dawidziak M: Clinical effects of multidrug resistance in neoplasms. Onkol Prakt Klin 2005, 1, 1, 18-26.
12. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9, 105-127.
13. Leonard G, Fojo T, Bates S: The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-424. (Pubitemid 37238869)
14. Wind N, Holen I: Multidrug resistance in breast cancers: from in vitro models to clinical studies. Int J Breast Cancer 2011, 1-12.
15. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H: Relationship between the expression of cyclooxygenase 2 and MDR1/Pglycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res 2005, 7, 5, 862-870.
16. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis MDR1/gp170 expression and its possibile functional significance. J Natl Cancer Inst 1997, 89, 917-931. (Pubitemid 27282064)
17. Burger H, Foekens JA, Look MP et al.: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with hemotherapeutic response. Clin Cancer Res 2003, 9, 827-836. (Pubitemid 36182621)
18. Takahashi K, Shibata T, Oba T, Ishikawa T, Yoshikawa M, Tatsunami R, Takahashi K, Tampo Y: Multidrug-resistance-associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells. Life Sci 2009, 84, 211-217.
19. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F: The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006, 7, 893-909.
20. Atalay C, Demirkazik A, Gunduz U: Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer. J Chemother 2008, 20, 734-739.
21. Deeley RG, Westlake C, Cole SP: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006, 86, 849-899. (Pubitemid 44033384)
22. Nooter K, Brutel de la Riviere G, Look MP: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997, 76, 4, 486-493. (Pubitemid 27331214)
23. Maciejczyk A, Jagoda E, Wysocka T, Matkowski R, Györffy B, Lage H, Surowiak P: ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res 2012 Apr, 18(2), 331-342.
24. Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 2006, 12, 23, 7149-7158. (Pubitemid 44974516)
25. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Surowiak P: Analysis of BCRP expression in breast cancer patients. Ginekol Pol 2012, 83, 9, 681-687.
26. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Lage H, Surowiak P: Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res 2012, 32, 8, 3177-3184.
27. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer H-D, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba Ch, Nitz U, Harbeck N: Y-Box-Binding Protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J ClinOncol 2009, 27, 6144-6151.
28. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 2004, 108, 930-936. (Pubitemid 38112624)
29. Maciejczyk A, Szelachowska J, Szynglarewicz B, Szulc R, Szulc A, Wysocka T, Jagoda E, Lage H, Surowiak P: CD46 expression is an unfavorable prognostic factor in breast cancer cases. Appl Immunohistochem Mol Morphol. 2011, 19, 540-546.
30. Seghal P: Epigenetic control of activity manifested by STAT3 transcription factor in neoplastic cells [in Polish]. Współ Onkol 2006, 10, 8, 373-377.
31. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R: Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 2007, 5(8), 823-832. (Pubitemid 47294810)
32. Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008 Apr, 34(4), 357-3564.
33. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ: The role of S100 genes in breast cancer progression. Tumour Biol 2011 Jun, 32(3), 441-450.
34. Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, Lupo C, Roz E, Pucci-Minafra I: Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 2010, 10, 476.
35. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Lage H, Surowiak P: Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res 2012, 32, 8, 3177-3184.
36. Gyo{combining double acute accent}rffy B, Benke Z, Lánczky A, Balázs B, Szállási Z, Timár J, Schäfer R: RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 2012, 132, 3, 1025-1034.
37. Gyo{combining double acute accent}rffy B, Lánczky A,Eklund A, Denkert C, Budczies J, Li Q, Szállási Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123, 725-773.